Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.50 |
| ▸ | PGK2 | P07205 | 1/20 | 0.50 |
| ▸ | PGD | P52209 | 4/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.40 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.40 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.40 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL8180825 | 0.96 | PGK1 (0.47) | PGK1PGK2PGDLPAR1LPAR5 | |
| Glycine SCHEMBL9225465 | 0.95 | PGK1 (0.46) | PGK1PGK2PGDLPAR1LPAR5 | |
| Hydrogen Peroxide SCHEMBL27990255 | 0.88 | PGK1 (0.56) | PGK1PGK2PGDLPAR1LPAR5 | |
| SCHEMBL7341 | 0.86 | PGK1 (0.52) | PGK1PGK2PGDLPAR1LPAR5 | |
| SCHEMBL14278847 | 0.86 | PGK1 (0.52) | PGK1PGK2PGDLPAR1LPAR5 | |
| SCHEMBL213379 | 0.86 | PGK1 (0.52) | PGK1PGK2PGDLPAR1LPAR5 | |
| SCHEMBL6655023 | 0.86 | PGK1 (0.52) | PGK1PGK2PGDLPAR1LPAR5 | |
| SCHEMBL14278848 | 0.86 | PGK1 (0.52) | PGK1PGK2PGDLPAR1LPAR5 | |
| SCHEMBL7340 | 0.86 | PGK1 (0.52) | PGK1PGK2PGDLPAR1LPAR5 | |
| Monoethanolamine SCHEMBL5181889 | 0.85 | PGD (0.44) | PGK1PGK2PGDLPAR1LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150342989-A1 | COMPOSITIONS COMPRISING NON STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF | ALEX PHILIP (US) | 2015-12-03 | — | — | US | disclosed |
| US-9084769-B2 | Compositions comprising non steroidal anti-inflammatory drugs and methods for use thereof | ALEX PHILLIP (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130142869-A1 | Compositions Comprising Non Steroidal Anti-inflammatory Drugs and Methods for Use Thereof | ALEX PHILLIP (US) | 2013-06-06 | — | — | US | disclosed |
| US-6610309-B2 | Vaccines; mixture of antigen and water solubility organometallic compound | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES (S.E.P.P.I.C.) (FR) | 2003-08-26 | — | — | US | disclosed |
| US-20010033845-A1 | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence | GANNE VINCENT (FR) | 2001-10-25 | — | — | US | disclosed |
| US-6274149-B1 | FOR INCREASING IN IMMUNE RESPONSE | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES (S.E.P.P.I.C.) (FR) | 2001-08-14 | — | — | US | disclosed |
| US-6251407-B1 | AND ADJUVANT SELECTED FROM MANGANESE GLUCONATE, CALCIUM GLUCONATE, ZINC GLUCONATE, CALCIUM FRUCTOHEPTONATE, ZINC GLUCOHEPTONATE, OR CALCIUM GLYCEROPHOSPHATE AND AN OILY PHASE ESTER OF ETHOXYLATED FATTY ACIDS; IMMUNOSTIMULATORY | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMQUE (FR) | 2001-06-26 | — | — | US | disclosed |
| EP-0825875-B1 | THERAPEUTIC COMPOSITION COMPRISING AN ANTIGEN OR AN IN VIVO GENERATOR FOR GENERATING A COMPOUND COMPRISING AN AMINO ACID SEQUENCE | SEPPIC SA (FR) | 2000-06-21 | — | — | EP | disclosed |
| EP-0825875-A1 | THERAPEUTIC COMPOSITION COMPRISING AN ANTIGEN OR AN IN VIVO GENERATOR FOR GENERATING A COMPOUND COMPRISING AN AMINO ACID SEQUENCE | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES, S.E.P.P.I.C. (FR) | 1998-03-04 | — | — | EP | disclosed |
| WO-1996032964-A1 | THERAPEUTIC COMPOSITION COMPRISING AN ANTIGEN OR AN IN VIVO GENERATOR FOR GENERATING A COMPOUND COMPRISING AN AMINO ACID SEQUENCE | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES-SEPPIC (FR) | 1996-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010033845-A1 | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence | CD74, TP53, HLA-DRB1 | PGK1 4482/4885PGK2 4312/4885PGD 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.